biotech
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis. The biotechnology firm’s shares experienced a significant surge of 55% this morning after the announcement, but despite this increase, they are still down approximately 35% from their highest point over the past 52 weeks. Why is it significant for Scinai stock?Dr. Tamar Ben-Yedidia, Chief Scientist at SCNI, highlighted the milestone achievement, confirming that the NanoAb effectively neutralizes bot...
Invezz
Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company’s investigational treatment for Alzheimer’s disease. Longeveron stock is still down about 60% versus the start of 2024. Why is it significant for Longeveron stock?The Regenerative Medicine Advanced Therapy designation comes with regulatory benefits that enable developers like LGVN to move faster in making their products available in the market. Lomecel-B met the success threshold in patients with mild AD in Clear Mind (Phase 2a trial...
Invezz
Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday. HyBryte is the biopharmaceutical firm’s treatment for early-stage cutaneous T-cell lymphoma. Soligenix stock rallied a whopping 400% following the interim results today. Here’s why it matters for Soligenix stockSoligenix has so far enrolled six patients in the aforementioned clinical study. Three of them met the minimum threshold for the treatment to be called a success within eighteen weeks. The Nasdaq-listed firm is committed to signing up a total of 50 patients eventually to the ongoi...
Invezz
Shares of Annovis Bio Inc (NYSE: ANVS) more than doubled on Tuesday after the biotech firm reported positive late-stage data for buntanetap. Buntanetap is the candidate treatment of ANVS for Parkinson’s disease. At the time of writing, Annovis stock is trading at $10.50 – still down some 45% versus the start of 2024. What does the data mean for Annovis stock?Buntanetap was shown to be effective in improving motor and nonmotor activities in a Phase 3 trial. It helped patients of Parkinson’s with overall cognitive function as well. Maria Maccecchini – the chief executive of Annovis Bio said in a...
Invezz
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it matter for Humacyte stock?The Acellular Tissue Engineering Vessel of the company based out of North Carolina, United States caters to patients with advanced peripheral artery disease. ATEV is implantable and is used in vascular replacement and repair. Dr. Cindy Cao – the chief regulatory officer of Humacyte said in a press release today: We are exc...
Invezz
Cassava Sciences (NASDAQ: SAVA) stock price has become a fallen angel. Once a high popular stock, it has crashed by over 45% this year and by more than 90% from its all-time high, giving it a market cap of over $530 million. At its peak, the company had a valuation of over $7.4 billion. Fall from grace continuesCassava Sciences, a leading company in Alzheimer’s research, was one of the hottest companies among traders. Its popularity soared in 2021 as most investors focused on Alzheimer after the FDA approved Biogen’s aducanumab, which it started selling at $26,500 per year. Recently, however, ...
Invezz
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it significant for Alnylam Pharmaceuticals stock?Vutrisiran demonstrated significant efficacy in reducing mortality and cardiovascular complications in the aforementioned study. It’s a drug that targets transthyretin amyloidosis with cardiomyopathy – a condition that stiffens the heart and impairs blood pumping. Pushkal Garg – the chief medical offi...
Invezz
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sciences stock valued at a 75% premiumANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has also agreed to 50 cents a share of additional payout provided that the acquiree hits certain revenue targets in 2026 and 2027. Nikhil Lalwani – the chief executive of $ANIP said in a press release on Monday: We believ...
Invezz
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-time high. Why is it significant for Zealand Pharma stock?Petrelintide – a long-acting amylin analog of Zealand Pharma showed significant efficacy in a 16-week trial, as per its press release on Friday. Participants receiving high doses successfully lowered their body weight by 8.6% versus only 1.7% observed in the placebo group. Only one participant out of a total of 48 had to withdraw from the stud...
Invezz
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company’s treatment for Duchenne muscular dystrophy. Why is it significant for Sarepta Therapeutics stock?The FDA granted accelerated approval for a label expansion of “delandistrogene moxeparvovec” to include non-ambulatory patients on Thursday. The decision is significant for individuals with DMD who have lost the ability to walk. Jerry Mendell – the co-inventor of Elevidys said in a press release%2C...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら